Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25. Please visit the Smith+Nephew booth during ICSES to learn more about the following technologies:
TENDON SEAM Rotator Cuff Repair System
Recently acquired by Smith+Nephew, the TENDON SEAM System is a unique rotator cuff repair solution that offers superior load sharing designed to maximize repair strength throughout the healing period.1-4,*,** The construct features multiple tightly spaced 2x10mm anchors connected by a continuous stitch designed to distribute forces across the repaired tendon with a seam of fixation perpendicular to the direction of load. Biomechanical testing demonstrates a 2X increase in repair strength and 10X decrease in gap formation compared with traditional techniques, 1-4,* with encouraging early clinical outcomes.5 View the TENDON SEAM Rotator Cuff Repair System webpage here.
REGENETEN◊ Bioinductive Implant
With more than 250,000 procedures6 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, demonstrating reduced risk of retear*** and benefits for patient recovery.7-9,± The bioinductive implant, with highly purified, highly porous, highly oriented collagen fibers, supports the body’s natural healing response to facilitate the formation of new tissue.10-14 A study published earlier this year concluded that early recovery time was halved following isolated use of the REGENETEN Implant for partial thickness tears when compared with a traditional suture anchor repair.15,±,‡ Patients also enjoyed a better shoulder-related quality of life at 6 weeks and 3 months.15,±,‡ Learn more about the REGENETEN Bioinductive Implant in partial-thickness rotator cuff tears, including the recent 4-star recommendation from AAOS for bioinductive implants, by visiting the webpage here.
Q-FIX◊ KNOTLESS 2.8 All-Suture Anchor – Launching at ICSES!
The Q-FIX KNOTLESS 2.8 All-Suture Anchor is designed for the shoulder surgeon that wants best-in-class reliability,16,† but in a knotless construct which allows fine-tuned tensioning of soft tissue. The Q-FIX KNOTLESS 2.8 Anchor has the versatility to meet the needs of various surgical procedures, tissue/bone quality, or surgeon preference, in different anatomies and surgical procedures. Learn more about the Q-FIX KNOTLESS family of all-suture anchors, by visiting the webpage here.
Differentiated shoulder arthroplasty technology for personalized care
CORIOGRAPH◊ Pre-Op Planning and Modeling Services and CORI◊ SHOULDER Handheld Robotics Arthroplasty with the AETOS◊ Shoulder System offer a complete robotic procedure supporting handheld robotic execution of the humerus and glenoid, across both anatomic and reverse procedures.
Skill amplified. The freedom of handheld robotics.
The best technology works naturally with surgical skill. The CORI XT Handheld Robotics Platform seamlessly integrates with current surgical workflows and was designed with a footprint tailored to the unique needs of hospitals and ambulatory surgical suite settings.17 It has a leaner platform configuration which moves easily between rooms.18,¥,
For more information about CORIOGRAPH Pre-Op Planning Services and CORI SHOULDER Handheld Robotics Arthroplasty, please visit the webpage here. If you will be attending ICSES, be sure to join our CORI SHOULDER Handheld Robotics Arthroplasty evening event on Sept 22. Click here to register: https://lnkd.in/eM5CJ3QW. Spaces are limited.
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
*In biomechanical testing in human cadavers
**compared to traditional techniques
***Compared to standard repairs alone in medium or large full-thickness tears. 12 month re-tear rate - 8.3% vs 25.8% Relative risk=0.32 [95% Confidence Interval 0.13-0.83]; p=0.0106.
±Compared to takedown and (suture anchor) repair.
‡Rehabilitation protocols differed between treatment groups: isolated REGENETEN Implant use employed a faster post-op rehab protocol vs traditional repair.
†As compared to the competitive device in cyclic benchtop testing
¥Compared to Mako™ and ROSA®
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
